CancerAACR D3: ONM-421 shows antigen-independent tumor controlAt the American Association for Cancer Research’s inaugural Drug Discovery and Development conference (AACR D3), Onconano Medicine Inc. presented preclinical data on ONM-421, a pH-responsive polymer-drug conjugate nanoparticle developed using the company’s proprietary ON-BOARD platform.